CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice

Michael Zimmer, Pradeep Bista, Ericka L. Benson, Diana Y. Lee, Feng Liu, Dominic Picarella, Rick B. Vega, Chi B. Vu, Maisy Yeager, Min Ding, Guosheng Liang, Jay D. Horton, Robert Kleemann, Teake Kooistra, Martine C. Morrison, Peter Y. Wielinga, Jill C. Milne, Michael R. Jirousek, Andrew J. Nichols – 12 May 2017 – CAT‐2003 is a novel conjugate of eicosapentaenoic acid (EPA) and niacin designed to be hydrolyzed by fatty acid amide hydrolase to release EPA inside cells at the endoplasmic reticulum.

Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection

Romain Désert, Florian Rohart, Frédéric Canal, Marie Sicard, Mireille Desille, Stéphanie Renaud, Bruno Turlin, Pascale Bellaud, Christine Perret, Bruno Clément, Kim‐Anh Lê Cao, Orlando Musso – 12 May 2017 – Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular phenotypes, raising major challenges in clinical management. HCCs detected by surveillance programs at an early stage are candidates for potentially curative therapies (local ablation, resection, or transplantation). In the long term, transplantation provides the lowest recurrence rates.

Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen

Edward J. Gane, Mitchell L. Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine A.M. Stedman, Mitchell N. Davis, Federico Hinestrosa, Hadas Dvory‐Sobol, K.C. Huang, Anu Osinusi, John McNally, Diana M. Brainard, John G. McHutchison, Alex J. Thompson, Mark S. Sulkowski, GS‐US‐342‐1553 Investigators – 12 May 2017 – The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct‐acting antiviral–based therapies remains unclear.

Factors influencing decisions about a career in hepatology: A survey of gastroenterology fellows

Sarah M. Ordway, Manish B. Singla, Patrick E. Young, Rohit Satoskar, Ryan M. Kwok – 12 May 2017 – Despite an unmet need for hepatologists in the United States, every year transplant hepatology (TH) fellowship positions remain unfilled. To address this, we investigated factors that influence trainee decisions about pursuing a career in hepatology.

Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice

Davor Slijepcevic, Reinout L.P. Roscam Abbing, Takeshi Katafuchi, Antje Blank, Joanne M. Donkers, Stéphanie van Hoppe, Dirk. R. de Waart, Dagmar Tolenaars, Jonathan H.M. van der Meer, Manon Wildenberg, Ulrich Beuers, Ronald P.J. Oude Elferink, Alfred H. Schinkel, Stan F.J. van de Graaf – 12 May 2017 – The Na+‐taurocholate cotransporting polypeptide (NTCP/SLC10A1) is believed to be pivotal for hepatic uptake of conjugated bile acids. However, plasma bile acid levels are normal in a subset of NTCP knockout mice and in mice treated with myrcludex B, a specific NTCP inhibitor.

Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease

Jeffrey B. Schwimmer, Cynthia Behling, Jorge Eduardo Angeles, Melissa Paiz, Janis Durelle, Jonathan Africa, Kimberly P. Newton, Elizabeth M. Brunt, Joel E. Lavine, Stephanie H. Abrams, Prakash Masand, Rajesh Krishnamurthy, Kelvin Wong, Richard L. Ehman, Meng Yin, Kevin J. Glaser, Bogdan Dzyubak, Tanya Wolfson, Anthony C. Gamst, Jonathan Hooker, William Haufe, Alexandra Schlein, Gavin Hamilton, Michael S. Middleton, Claude B.

Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease

Jeffrey B. Schwimmer, Cynthia Behling, Jorge Eduardo Angeles, Melissa Paiz, Janis Durelle, Jonathan Africa, Kimberly P. Newton, Elizabeth M. Brunt, Joel E. Lavine, Stephanie H. Abrams, Prakash Masand, Rajesh Krishnamurthy, Kelvin Wong, Richard L. Ehman, Meng Yin, Kevin J. Glaser, Bogdan Dzyubak, Tanya Wolfson, Anthony C. Gamst, Jonathan Hooker, William Haufe, Alexandra Schlein, Gavin Hamilton, Michael S. Middleton, Claude B.

Atovaquone/proguanil‐induced autoimmune‐like hepatitis

Benedetta Terziroli Beretta‐Piccoli, Giorgina Mieli‐Vergani, Raffaela Bertoli, Luca Mazzucchelli, Charity Nofziger, Markus Paulmichl, Diego Vergani – 8 May 2017 – We report a novel association between the commonly used antimalarial medication atovaquone/proguanil and drug‐induced autoimmune‐like hepatitis. The patient developed severe liver disease fulfilling biochemical, immunologic, and histologic criteria for the diagnosis of autoimmune hepatitis after the inadvertent rechallenge with the offending drug, which had caused self‐limited hepatitic symptoms a year previously.

Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells

Neda Milosavljevic, Marina Gazdic, Bojana Simovic Markovic, Aleksandar Arsenijevic, Jasmin Nurkovic, Zana Dolicanin, Valentin Djonov, Miodrag L. Lukic, Vladislav Volarevic – 8 May 2017 – Mesenchymal stem cells (MSCs) are, due to immunomodulatory characteristics, considered as novel agents in the treatment of immune‐mediated acute liver failure. Although it is known that MSCs can regulate activation of T lymphocytes, their capacity to modulate function of neutrophils and natural killer T (NKT) cells, major interleukin (IL) 17–producing cells in acute liver injury, is still unknown.

Subscribe to